JP2016526920A - 最適化ａ−バルジを有する組換えベクター - Google Patents

最適化ａ−バルジを有する組換えベクター Download PDF

Info

Publication number
JP2016526920A
JP2016526920A JP2016533383A JP2016533383A JP2016526920A JP 2016526920 A JP2016526920 A JP 2016526920A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016533383 A JP2016533383 A JP 2016533383A JP 2016526920 A JP2016526920 A JP 2016526920A
Authority
JP
Japan
Prior art keywords
replication competent
retrovirus
sequence
recombinant replication
competent retrovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016526920A5 (enExample
Inventor
リン，エイミー，エイチ．
グルーバー，ハリー，イー．
イバネス，カルロス
ジョリー，ダグラス，ジェイ．
Original Assignee
トカジェン インコーポレーテッド
トカジェン インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トカジェン インコーポレーテッド, トカジェン インコーポレーテッド filed Critical トカジェン インコーポレーテッド
Publication of JP2016526920A publication Critical patent/JP2016526920A/ja
Publication of JP2016526920A5 publication Critical patent/JP2016526920A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016533383A 2013-08-05 2014-08-05 最適化ａ−バルジを有する組換えベクター Pending JP2016526920A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862433P 2013-08-05 2013-08-05
US61/862,433 2013-08-05
PCT/US2014/049831 WO2015021077A1 (en) 2013-08-05 2014-08-05 Recombinant vector with optimized a-bulge

Publications (2)

Publication Number Publication Date
JP2016526920A true JP2016526920A (ja) 2016-09-08
JP2016526920A5 JP2016526920A5 (enExample) 2017-09-14

Family

ID=52461883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533383A Pending JP2016526920A (ja) 2013-08-05 2014-08-05 最適化ａ−バルジを有する組換えベクター

Country Status (6)

Country Link
EP (1) EP3030659A4 (enExample)
JP (1) JP2016526920A (enExample)
CN (1) CN105579581A (enExample)
AU (1) AU2014306093A1 (enExample)
CA (1) CA2920049A1 (enExample)
WO (1) WO2015021077A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551239A (ja) * 2019-09-30 2022-12-08 シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ 動脈関連疾患を治療するための薬物およびその用途
JP2023525720A (ja) * 2020-05-11 2023-06-19 アビタス バイオ インコーポレイティッド Ｉｎ ｖｉｖｏ形質導入のためのベクター及び方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
US12421524B2 (en) 2018-09-24 2025-09-23 Merck Sharp & Dohme Llc Expression vectors for eukaryotic expression systems
CN114127121B (zh) 2019-08-12 2025-04-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
AU2022212007A1 (en) 2021-01-29 2023-09-07 Merck Sharp & Dohme Llc Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
WO2023057946A1 (en) 2021-10-07 2023-04-13 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
TW202334196A (zh) 2021-10-07 2023-09-01 英商阿法克塔生命科學有限公司 Pd-l1結合多肽
CA3248580A1 (en) 2022-04-29 2023-11-02 Purinomia Biotech, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS CAUSED BY EOSINOPHIL ACTIVITY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260568A1 (en) * 2004-04-30 2005-11-24 Min Gao Hepatitis C virus assays
JP2012503987A (ja) * 2008-09-26 2012-02-16 トカジェン インコーポレーテッド 組換えベクター
JP2013523754A (ja) * 2010-03-29 2013-06-17 トカジェン インコーポレーテッド 組み換えベクターを用いたがんの治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) * 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
US20110020814A1 (en) * 2009-06-05 2011-01-27 Ipierian, Inc. Methods and compositions for selection of stem cells
EP3546583A1 (en) * 2009-06-17 2019-10-02 Tocagen Inc. Producer cells for replication competent retroviral vectors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260568A1 (en) * 2004-04-30 2005-11-24 Min Gao Hepatitis C virus assays
JP2012503987A (ja) * 2008-09-26 2012-02-16 トカジェン インコーポレーテッド 組換えベクター
JP2012503986A (ja) * 2008-09-26 2012-02-16 トカジェン インコーポレーテッド 遺伝子治療ベクターおよびシトシンデアミナーゼ
JP2013523754A (ja) * 2010-03-29 2013-06-17 トカジェン インコーポレーテッド 組み換えベクターを用いたがんの治療

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUKE GM ET AL., J VIROL., vol. 66(3)(1992), JPN6018027135, pages 1602 - 1609, ISSN: 0003987920 *
KAMINSKI A. ET AL., RNA, vol. 4(6)(1998), JPN6018027134, pages 626 - 638, ISSN: 0003987919 *
ORLINGER K. ET AL., J. VIROL., vol. 81(22)(2007), JPN6018027136, pages 12619 - 12629, ISSN: 0003987918 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551239A (ja) * 2019-09-30 2022-12-08 シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ 動脈関連疾患を治療するための薬物およびその用途
JP7500715B2 (ja) 2019-09-30 2024-06-17 シャンハイ インスティチュート オブ マテリア メディカ，チャイニーズ アカデミー オブ サイエンシーズ 動脈関連疾患を治療するための薬物およびその用途
JP2023525720A (ja) * 2020-05-11 2023-06-19 アビタス バイオ インコーポレイティッド Ｉｎ ｖｉｖｏ形質導入のためのベクター及び方法

Also Published As

Publication number Publication date
CN105579581A (zh) 2016-05-11
EP3030659A4 (en) 2017-01-11
CA2920049A1 (en) 2015-02-12
AU2014306093A1 (en) 2016-03-17
WO2015021077A1 (en) 2015-02-12
AU2014306093A2 (en) 2016-04-21
EP3030659A1 (en) 2016-06-15

Similar Documents

Publication Publication Date Title
US11279949B2 (en) Recombinant vectors comprising 2A peptide
JP5992548B2 (ja) 組換えベクター
US10407666B2 (en) Recombinant vectors
JP6419706B2 (ja) ミニプロモーターカセットを含むレトロウイルスベクター
AU2014306093A2 (en) Recombinant vector with optimized A-bulge
JP2012503987A5 (enExample)
US20160222412A1 (en) Recombinant vector with stabilizing a-loop

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190305